Overview

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Status:
Terminated

Trial end date:
2019-09-09

Target enrollment:

Participant gender:

Summary

This is a randomized open label study to evaluate the long term safety of ASN002 in subjects with moderate to severe atopic dermatitis (AD).

Phase:

Phase 2

Details

Lead Sponsor:

Asana BioSciences